New Delhi: Without mincing words, Indian Medical Device Industry leader Rajiv Nath has launched a broadside against budget passed by PM Modi 0.2. Calling it a deeply disappointing budget so far as healthcare and medical device industry is considered, he has listed a number of disappointments.
Mr Nath, Forum Coordinator, All India Medical Devices (AiMeD) and a champion of ‘Make in India’, has expressed deep anguish over continued neglect of the domestic medical devices manufacturers by the government. Despite umpteen reminders, the Union Budget 2019-20 has not heeded to our suggestions on extending tax and non-tax protection to our industry.
‘We at AIMED are shell shocked to see that no action has been taken by the Govt. to stem the tsunami of imports of 24% now crossed 38800 Cr Rs that’s crushing Indian manufacturing, Mr Nath added.
‘It is strange to notice that since last 3 years , it is the first budget with zero mention on healthcare not even higher allocation for Ayushman Bharat,’ Said Mr. Rajiv Nath
Medium and Small Enterprises (MSME) dominated medical devices industry is staring at a worst jolt ever thanks to GST as imports become 11% cheaper and shoot up 24%. Data from the Commerce Ministry and compiled by AiMeD shows Imports of medical devices have increased by record 24 % at 7450 Cr ₹ from ₹31386 Cr in 2017-2018 to 38,837 Cr ₹ in 2018-2019.
‘Since the market is barely growing at 10-12%, a 24% increase in imports would mean further erosion of 10-30% in market share of domestic industry which may account for just 10 – 20% market share’, stated a visibly upset Mr. Rajiv Nath.
In other words, Sunrise sector of Medical Devices faces sunset year with 24 % sharp rise in imports if the Government does not take corrective measures to promote indigenous manufacturing.
This is indeed very sad, especially when the Government is taking credit for resounding success of its flagship policy dispensation of “Make In India”, envisioned to promote higher GDP growth and employment generation.
On the contrary, the Government seems to be telling the domestic medical devices manufacturers ‘Not To Make In India’ as it is promoting large scale imports of medical devices.
There is an urgent need for the Govt. to expedite steps to end the 80-90% import dependence forced upon us and an ever increasing import bill of over Rs 38,837 Crore, expedite steps for patients’ protection, stronger quality & Safety regulations, price controls to make medical devices and quality treatment accessible and affordable and ethical indigenous manufacturing viable .
Mr. Rajiv Nath claimed that after the goods and services tax (GST) on imported medical devices became cheaper by 11 per cent, the basic import tariff stands in the range of nil-to-7.5 per cent for most medical devices. Before the GST regime, imported medical devices attracted excise duty and special additional duty, over and above the import duty. After GST, only import duty and GST are levied. However, since one gets input credit in the GST regime, the effective taxation reduces, explained Nath.
While the Modi Government is touting the success of Make in India program, the beleaguered Medical Devices domestic industry is focusing on exports as they continue to lose market share to imports on account of lack of adequate tariff protection, lack of non tariff import barriers & unfair unethical market that favors perceived higher quality of familiar MNC brands with attractive trade margins and higher MRP vs unfamiliar unknown new Indian brands which even if lower priced against European or American or Japanese brands, if not Chinese, do not adequately induce retailers & hospitals to push their products nor do they have the deep pockets to match the sales promotion, marketing budgets to sponsor events of celebrity doctors.
Even as medical device makers in America allege the regulatory environment in India has hindered the growth of their export, the data suggests otherwise. India imports around 80 per cent of its medical devices requirement and a fourth of that comes from the US. The Top 5 Countries that India imports Medical Devices from are USA (21%), Germany (14%),Singapore (11%), China 10% and Netherlands (7%)
‘Exports have gone up a record 29%, 2840 Cr ₹ from 9908 Cr ₹ in 2017-18 to 12749 Cr ₹ in 2017-19 but the 2840 Cr ₹ gain is not enough to neutralize the 7450 Cr ₹ import increase. We are however happy to contribute another 4610 Cr ₹ to the negative trade imbalance of India .We are being globally competitive but not in our own market,’ Said Mr. Rajiv Nath
We estimated the market size at the retail and institutional level to be over 15 Billion $ with Domestic products now at less than 20% market share.
Mr. Nath opined “GoI needs to take policy decisions to give level playing field if not a strategic advantage to domestic Mfg while safeguarding consumers or India will remain 80-90% import dependent.”
We request the government
- To encourage employment and Make in India of Medical Devices and address 70-90% import dependency by a predictive nominal tariff protection policy as done for mobile phones to ensure a vibrant domestic industry & competitiveness and price stability driven by competing domestic player.
- To protect Consumers from exploitatively high MRP in Medical Devices by rationalized price controls and aid ethical marketing.
- To incentivize Quality in Healthcare Products in public healthcare procurements by preferential pricing for Q1 e.g. ICMED (QCI’s Indian Certification for Medical Devices) instead of L1 (lowest price) to ensure patients access acceptable quality
‘We stress these are vital and strategic to meet the health-for-all National agenda of PM Modi and aligned to the Health Policy 2017, to make quality healthcare accessible and affordable for common masses and to enable placing India among the Top 5 Medical Devices manufacturing hubs worldwide and end the 80-90% import dependence forced upon us and an ever increasing import bill of over Rs 38,837 Crore! Pseudo Manufacturing & Unethical marketing is harming consumers and disallowing manufacturing to succeed in India by well-meaning investors. We can repeat the success story of mobile phones by replicating the same strategies,’ said Mr. Nath.
